SCHEMBL13645773

SCHEMBL13645773

CCC(=O)C(=O)NC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.36
EPHX1 P07099 1/20 0.34
KDM4E B2RXH2 3/20 0.34
CYP2C9 P11712 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
FFAR3 O14843 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16391211 0.80 EPHX1 (0.41) EPHX1KDM4ELMNAPOLBHTT
SCHEMBL13967130 0.79 RAB9A (0.36) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL11469749 0.77 ALDH1A1 (0.37) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL13644761 0.77 RAB9A (0.35) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL6859267 0.76 KDM4E (0.46) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL28895183 0.75 RAB9A (0.34) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL11472085 0.73 CES2 (0.58) MEN1KMT2ATDP1ALDH1A1
SCHEMBL13644770 0.73 CACNA1H (0.35) RAB9AEPHX1KDM4ECYP2C9SMN1; SMN2
SCHEMBL6356662 0.72
SCHEMBL155565 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same PPP2CA, PPP4C, PPP6C RAB9A 3562/4885EPHX1 3369/4885KDM4E 243/4885
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 RAB9A 3155/4885EPHX1 1/4885KDM4E 905/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV RAB9A 2344/4885EPHX1 1325/4885KDM4E 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.